Thomson Reuters/Uni...
Health Care: Drugs
AcelRx Pharmaceuticals Inc. (ACRX: NASDAQ)
$6.68 -0.51 | -7.09%
05/17/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 2.39M | 1.07M | 0.00 | 0.00 |
| Cost of Sales | 0.00 | 0.00 | -479.00K | -481.00K |
| Gross Operating Profit | 2.39M | 1.07M | 479.00K | 481.00K |
| Selling, General, and Administrative Expenses | 7.20M | 6.80M | 3.99M | 3.53M |
| Research & Development | 24.91M | 13.62M | 8.19M | 15.50M |
| Operating Income before D & A (EBITDA) | -29.71M | -19.35M | -11.71M | -18.55M |
| Depreciation & Amortization | 985.00K | 708.00K | 479.00K | 481.00K |
| Interest Income | 0.00 | 52.00K | 4.00K | 33.00K |
| Other Income - Net | -1.37M | 1.51M | -765.00K | 121.00K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -32.06M | -18.50M | -12.95M | -18.88M |
| Interest Expense | 2.28M | 2.31M | 1.40M | 1.24M |
| Pre-Tax Income | -34.35M | -20.81M | -14.34M | -20.12M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -33.36M | -20.10M | -14.34M | -20.12M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -33.36M | -20.10M | -14.34M | -20.12M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -33.36M | -20.10M | -14.34M | -20.12M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-33.36M | -20.10M | -14.34M | -20.12M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -33.36M | -20.10M | -14.34M | -20.12M |
| Basic EPS from Continuing Ops. | -1.51 | -1.16 | -21.84 | -3.51 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -1.51 | -1.16 | -21.84 | -3.51 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -1.51 | -1.16 | -21.84 | -3.51 |
| Basic Normalized Net Income/Share | -1.51 | -1.16 | -21.84 | -3.51 |
| EPS fr Continuing Ops. | -1.51 | -1.16 | -21.84 | -3.51 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -1.51 | -1.16 | -21.84 | -3.51 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -1.51 | -1.16 | -21.84 | -3.51 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-1.51 | -1.16 | -21.84 | -3.51 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with ACRX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Under-$10 Moving Hig...
Latest ACRX Headlines from TheStreet
- 4 Biotech Stocks Under $10 Making Big Moves 04.09.13 | 02:04 pm
- 5 Stocks Poised for Breakouts 02.01.13 | 01:02 pm
- 5 Stocks Insiders Are Stuffing in Their Stockings 12.12.12 | 12:12 pm
- Dunkin' Brands Prices IPO Above Range 07.26.11 | 07:07 pm
- IPO Lessons From Pandora 02.16.11 | 01:02 pm
- IPO Watch: 2011 02.16.11 | 01:02 pm
- Gaskins Warns on Speculative Pharma IPOs
02.02.11 | 08:02 am
Press Releases for ACRX
- AcelRx Pharmaceuticals To Hold Fourth Quarter 2012 Financial Results Conference Call And Webcast On March 12, 2013 - PR Newswire 03.07.13 | 07:03 am
- AcelRx Top-line Data Show Primary Endpoint Achieved In Pivotal Phase 3 Study Of Sufentanil NanoTab PCA System For Post-Operative Pain In Major Open Abdominal Surgery Patients - PR Newswire 03.04.13 | 06:03 pm
- AcelRx Pharmaceuticals To Present At Two Upcoming Investor Conferences - PR Newswire 02.27.13 | 07:02 am
- AcelRx Pharmaceuticals Provides Clinical Trial Updates - PR Newswire 02.19.13 | 07:02 am
- AcelRx Appoints Adrian Adams To Board Of Directors As Chairman - PR Newswire 02.12.13 | 07:02 am
- AcelRx Pharmaceuticals Announces Exercise Of Option To Purchase Additional Shares - PR Newswire 12.14.12 | 12:12 pm
- AcelRx To Present Top-Line Data From Phase 3 Study Of Sufentanil NanoTab® PCA System Vs. IV PCA Morphine At The 66th Annual PostGraduate Assembly In Anesthesiology Held In New York City - PR Newswire 12.14.12 | 07:12 am
- AcelRx Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock - PR Newswire 12.06.12 | 10:12 pm
- AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock - PR Newswire 12.05.12 | 06:12 am
- AcelRx Pharmaceuticals To Present At The Piper Jaffray 24th Annual Healthcare Conference - PR Newswire 11.20.12 | 07:11 pm
Partner Headlines for ACRX
- UPDATE: Jefferies Initiates AcelRx Pharmaceuticals with Buy on Expected FDA Approval for ARX-01 - Benzinga 04.08.13 | 09:04 am
- After-Hours Earnings Report for March 12, 2013 : KW, DOLE, ACAD, GCA, GNMK, AVID, WSR, KTOS, GERN, ACRX, FOLD, GCAP - NASDAQ 03.12.13 | 06:03 pm
- AcelRx Pharma: Pain Drug Developer With A Pair Of Q1 2013 Phase III Catalysts - Seeking Alpha 12.22.12 | 09:12 am
- FROM EARLIER: AcelRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority Study of Sublingual Sufentanil NanoTab® PCA System vs. IV PCA Morphine for Post-Operative Pain - Benzinga 11.15.12 | 08:11 am
- New IPO Filings And What's On The Horizon - Seeking Alpha 02.03.12 | 06:02 pm
- Company News for May 27, 2011 - Corporate Summary - Zacks 05.27.11 | 10:05 am
